Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

Neumora Therapeutics, Inc.

NMRANASDAQEQUITYCurrent

Quarterly Report

Filed Nov 1, 2023Accepted Nov 1, 2023, 4:05 PM EDTCIK 1885522Accession 0000950170-23-057424
Share

Company context

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Current securities

Recent company filings

  1. 4 filingAug 21, 2026
  2. 4 filingAug 21, 2026
  3. 4 filingAug 21, 2026
  4. 144 filingAug 21, 2026
  5. 144 filingAug 20, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗